Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

Proteomics-based Identification of RS/DJ-1 as a Novel Circulating Tumor Antigen in Breast Cancer

François Le Naour, David E. Misek, Melissa C. Krause, L. Deneux, Thomas J. Giordano, S. Scholl and Samir M. Hanash
François Le Naour
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Misek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa C. Krause
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Deneux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Giordano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Scholl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samir M. Hanash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Screening of autoantibodies in breast cancer. A, proteome profile of SUM-44 cells. The proteins from whole-cell extracts of SUM-44 cells were separated by 2-D PAGE and silver stained. B, close up sections showing Western blot performed with lysates from SUM-44 cells and sera from healthy controls or from breast cancer patients as primary antibody. An antihuman IgG was used as a secondary antibody. The three spots recognized by sera from patients with breast cancer are indicated by open arrows.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Characterization of RS by Western blot. The proteins from the breast cell line SUM-44 were separated by 2-D PAGE. A, the proteins were transferred to a PVDF membrane, and Western blotting was performed using the rabbit polyclonal antibody directed against RS or the mouse monoclonal antibody directed against DJ-1. B, the proteins from SUM-44 cells were silver stained. The five different forms of RS/DJ-1 are labeled. Only a part of the gel is shown.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    RS/DJ-1 expression analysis by Western blot. A, the proteins from several cell lines were separated by 2-D PAGE and transferred to a PVDF membrane. The expression of RS/DJ-1 was investigated by Western blotting using the rabbit polyclonal antibody directed against RS and whole-cell extracts from the cell lines SUM-44 (Breast), HuH7 (Liver), A549 (Lung), and U87 (Brain). B, RS/DJ-1 expression was investigated in normal mammary epithelium as well as in three primary breast tumors.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    IHC. Sections of breast tissue containing healthy and tumor cell areas were immunostained with the rabbit polyclonal antibody against RS. The nuclei in the epithelial cells from the healthy tissue were stained with a high intensity, whereas most of nuclei in the carcinoma area were not stained. These results are representative of the observations for 20 slides.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Occurrence of RS/DJ-1 in the secreted protein fraction of SUM-44. Proteins from whole cell extracts (WCE; left) or from supernatant of SUM-44 cells (SN; right) were separated by 2-D PAGE and transferred to a PVDF membrane. Expression of RS/DJ-1 and β-tubulin was determined by Western blotting experiments.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Presence of the protein RS/DJ-1 in the sera from patients with breast cancer. A, serum proteins from breast cancer patients or from healthy women were separated by 1-D PAGE and transferred to a PVDF membrane. Western blotting experiments were performed with the mouse monoclonal antibody against DJ-1. B, serum containing the protein RS/DJ-1 were used for Western blotting experiments after 2-D PAGE. The different RS/DJ-1 isoforms of the protein RS/DJ-1 are circulating.

Tables

  • Figures
  • Table 1

    Clinical characteristics of subjects with breast cancer

    PatientAge (yrs)StagePathologyRS AbaRS Ag−
    138T2N1M0Infiltrat. ductalAb+Ag+
    250T1N0M0DIAb−Ag−
    354T2N0M0DIAb−Ag−
    457T3N1bM0DIAb−Ag−
    584T2N0M0MucinousAb−Ag+
    672T2N0M0DIAb−Ag−
    752T1N0M0DIAb−Ag−
    878T4dN3M0DIAb−Ag−
    986T3N0M0DIAb−Ag+
    1037T1N0M0Infiltrat. lobulaAb−Ag−
    1172T2N0M0DIAb−Ag−
    1247T2N0M0DIAb+Ag+
    1372T1N0M0Infiltrat. lobulaAb−Ag−
    1472T2N0M0DIAb−Ag−
    1542T2N1M1DIAb−Ag−
    1649T1N0M0DIAb−Ag+
    1762RecurrenceInfiltrat. lobulaAb−Ag−
    1866T0N0M0IntraductalAb−Ag+
    1965PreinvasiveIntraductalAb−Ag+
    2056T4N1aM1DIAb−Ag−
    2146T1N0DIAb−Ag+
    2255T1N0M0DIAb−Ag+
    2345T2N0DIAb−Ag−
    2465T3N0M3DIAb−Ag−
    2564T3N1aM0DIAb+Ag+
    2663T2N0M0DIAb−Ag−
    2777T2N0DIAb−Ag−
    2887T2NXM0DIAb−Ag−
    2975DIAb+Ag+
    3040T1N0M0DIAb−Ag−
    • a Ab, antibody; Ag, antigen; DI, Infiltrat. ductal.

  • Table 2

    Assignment of peptide masses to the human RS/DJ-1 sequence

    Analysis by MALDI-TOF mass spectrometry of the peptide masses followed by search in the NCBI database.
    Measured mass (Da)Matched (Da)Delta (ppm)ResiduesSequence
    Trypsin
    875.8823875.9826114.504142–48DPVQCSR
    1159.37991159.289078.371990 –98EILKEQENR
    1547.06381546.7425207.729849 –62DVVICPDASLEDAK
    1677.43431676.6554285.604513 –27GAEEMETVIPVDVMR
    2283.21222282.7201215.5653100–122GLIAAICAGPTALLAHEIGFGSK
    2410.92192410.894911.195699–122KGLIAAICAGPTALLAHEIGFGSK
    2385.88402835.9015−7.32876–27ALVILAKGAEEMETVIPVDVMR
    2586.10422585.883385.413864–89EGPYDVVVLPGGNLGAQNLSESAAVK
    Chymotrypsin
    983.4457983.1567293.912768 –77DVVVLPGGNL
    1013.27041013.2734−3.00801–10ASKRALVILa
    1072.03841072.3168−259.6541102 –112IAAICAGPTAL
    1146.98281147.2344−219.3025142 –151SENRVEKDGL
    1186.47841186.2706175.1733154 –164TSRGPGTSFEF
    2942.12742942.5262−135.543411–38AKGAEEMETVIPVDVMRRAGIKVTVAGL
    3235.23693234.6441183.278939–67AGKDPVQCSRDVVICPDASLEDAKKEGPY
    Glu-C
    760.9006760.828195.2907144 –149NRVEKD
    1117.11931117.3111−171.665450 –59VVICPDASLE
    1352.89361352.6664168.0011177 –189VAAQVKAPLVLKD
    1375.46941375.6134−104.7112164–176FALAIVEALNGKE
    1435.48791435.6256−95.9287150–163GLILTSRGPGTSFE
    1567.57861567.7887−134.003769–84VVVLPGGNLGAQNLSE
    1598.67011598.8685−124.0827117–131IGCGSKVTTHPLAKD
    1598.84.021598.8900−31.13751–16ASKRALVILAKGAEEa
    1678.67521678.8892−127.4453148–163KDGLILTSRGPGTSFE
    2971.59112971.395565.8432117–143IGFGSKVTTHPLAKDKMMNGGHYTYSE
    2972.29672971.8563171.222260–84DAKKEGPYDVVVLPGGNLGAQNLSE
    • a The peptide mass match is compatible with an Acet-N modification.

PreviousNext
Back to top
November 2001
Volume 7, Issue 11
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Proteomics-based Identification of RS/DJ-1 as a Novel Circulating Tumor Antigen in Breast Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Proteomics-based Identification of RS/DJ-1 as a Novel Circulating Tumor Antigen in Breast Cancer
François Le Naour, David E. Misek, Melissa C. Krause, L. Deneux, Thomas J. Giordano, S. Scholl and Samir M. Hanash
Clin Cancer Res November 1 2001 (7) (11) 3328-3335;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Proteomics-based Identification of RS/DJ-1 as a Novel Circulating Tumor Antigen in Breast Cancer
François Le Naour, David E. Misek, Melissa C. Krause, L. Deneux, Thomas J. Giordano, S. Scholl and Samir M. Hanash
Clin Cancer Res November 1 2001 (7) (11) 3328-3335;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Advances in Brief

  • Development and Applications of a β-Catenin Oligonucleotide Microarray
  • Clinicopathologic Assessment of Postradiation Sarcomas
  • Expression of Constitutively Active Akt-3 in MCF-7 Breast Cancer Cells Reverses the Estrogen and Tamoxifen Responsivity of these Cells in Vivo
Show more Advances in Brief

Molecular Oncology, Markers, Clinical Correlates

  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
  • Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer
  • Transcription Factor AP-2γ Is a Developmentally Regulated Marker of Testicular Carcinoma In situ and Germ Cell Tumors
Show more Molecular Oncology, Markers, Clinical Correlates
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement